GSK Plc (GSK)
58.93
+0.39
(+0.67%)
USD |
NYSE |
Feb 13, 16:00
59.17
+0.24
(+0.41%)
After-Hours: 20:00
GSK Cash from Investing (Quarterly) : -3.184B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -1.501B |
| Mereo BioPharma Group Plc | 0.3027M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -0.0656M |
| AnaptysBio, Inc. | 103.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.744B |
| Cash from Financing (Quarterly) | 1.089B |
| Free Cash Flow | 5.712B |
| Free Cash Flow Per Share (Quarterly) | 0.6832 |
| Free Cash Flow to Equity (Quarterly) | 1.457B |
| Free Cash Flow to Firm (Quarterly) | 1.587B |
| Free Cash Flow Yield | 4.72% |